november AG
november AG english
november AG continues dynamic growth
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG continues dynamic growth
november AG consequently continued the development of ground-breaking
biotechnological methods in the fields of product security and brand protection,
Molecular Diagnosis, and Molecular Therapy during the last financial year 2001.
IDENT technology, a joint development with Siemens, is close to market
readiness and was presented on several trade fairs with great success, lately
together with Bundesdruckerei GmbH at CeBit 2002. Cluster-labeling of smart-
cards chips is evaluated together with Infineon AG since early 2002.
Despite the deconsolidation of the la fontaine companies, effective as of 31 May
2001, the november group achieved a sharp increase in turnover of more than 100
% to EUR 3.7 million (previous year: EUR 1.8 million). This was primarily due
to sales of medical and biotechnological products by the PEQLAB Biotechnologie
GmbH subsidiary. In order to ensure fast development of the projects, R&D
expenditure rose in 2001 as planned to EUR 5.2 million (previous year: EUR 3.3
million) and the average number of employees was increased from 69 in 2000 to 87
in 2001. Payroll expenses hence rose from EUR 2.9 million to EUR 4.5 million
during the financial year 2001. Together with the increase of R&D activities,
this resulted in an expected rise in operating costs. The group deficit for the
financial year amounted to EUR 7.1 million (previous year: EUR 4.2 million),
EBIT changed from EUR -6.3 million to EUR -8.6 million.
As of 31 December 2001, the balance sheet total amounted to EUR 35.0 million
(previous year: EUR 43.3 million). Shareholders’ equity of the november group
totaled EUR 32.0 million at the end of year (previous year: EUR 37.5 million).
The equity ratio therefore rose to approx. 92 % (previous year: 87 %).
At the end of 2001, the total short and medium term cash and cash equivalents of
the company amounted to EUR 24.1 million (previous year: EUR 35.1 million), the
operating decrease in liquidity amounted to EUR 8.5 million during the past
financial year. november AG possesses a sound financial basis, which will be
sufficient to cover all the liquidity needs of the november group for the coming
years until reaching break-even.
Within the current year, the november group expects a further significant growth
in consolidated turnover.
november AG, Christian Fenner, Tel.: +49 (0)9131-750 88 874, fenner@november.de
end of ad-hoc-announcement (c)DGAP 25.03.2002
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, München, Hannover und Stuttgart
252059 Mär 02
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden